S&P 500 Industrials Sector SEC Filings — March 23, 2026

23-03-2026

Apogee Acquisition Corp, a Cayman Islands-based blank check company (SPAC), filed Amendment No. 1 to its S-1 registration statement on March 23, 2026, for an initial public offering of 25,000,000 units at $10.00 each, targeting $250M in proceeds, with a focus on acquiring technology-driven businesses in software, hardware, compute infrastructure, and related sectors. The Sponsor, Apogee Acquisition Sponsor LLC, will purchase 470,000 private placement units for $4.7M concurrently, while founder shares (9,583,333 initially purchased for $25,000) carry anti-dilution rights that may cause material dilution to public shareholders upon conversion. Underwriters have a 45-day option for up to 3,750,000 additional units.

• ·Warrants exercisable at $11.50 per Class A share, becoming exercisable 12 months post-IPO or upon business combination, expiring 5 years after combination.
• ·Public shareholders can redeem shares at ~$10.00 per share from trust account upon business combination, with no minimum net tangible assets requirement.
• ·Founder shares represent ~25% ownership post-IPO (excluding private placement), convertible to Class A on 1:1 basis subject to anti-dilution adjustments.
• ·Up to 15% redemption limit per shareholder/group if shareholder approval required (not tender offer).

23-03-2026

Faraday Future Intelligent Electric Inc. announced that the SEC has concluded its years-long investigation into 2021 PIPE and SPAC-related transactions with no enforcement action against the Company, founder and Co-CEO YT Jia, President Jerry Wang, or other team members, removing a major regulatory overhang. This provides clarity to pursue strategic financing, partnerships, Nasdaq compliance within 180 days without a reverse split, and focus on EAI vehicles and robotics. However, forward-looking statements highlight ongoing risks including liquidity shortages, potential delisting if share price falls below $0.10 for 10 days, substantial dilution needs, and execution challenges on vehicle deliveries and robotics.

• ·Nasdaq compliance notice received March 20, 2026, granting 180-day period to meet $1 minimum bid price without reverse stock split.
• ·SEC investigation originated from independent director probe in October 2021 related to SPAC merger.
• ·FF 91 deliveries began in 2023; Super One deliveries planned for 2026; Embodied AI Robotics sales beginning in 2026.

23-03-2026

Apogee Therapeutics announced positive 52-week maintenance data from Part A of the Phase 2 APEX trial of zumilokibart (APG777) in moderate-to-severe atopic dermatitis, demonstrating durable EASI 75 maintenance of 75% (3-month dosing) and 85% (6-month) among Week 16 responders, with overall responses of 88% and 81%, and deepening efficacy across endpoints. However, overall vIGA 0/1 responses were lower for 6-month dosing at 52% versus 72% for 3-month, EASI 90 at 48% versus 75%, and EASI 100 at 19% versus 41%. Zumilokibart was well-tolerated with 71.4% TEAEs, rare serious events (0.8%), and low discontinuations (3.4%), supporting Phase 3 initiation in 2H 2026 for a potential $50B AD market launch in 2029.

• ·APEX Part B 16-week induction data expected Q2 2026
• ·Phase 3 trial initiation for zumilokibart in AD expected 2H 2026
• ·Phase 1b APG279 vs. DUPIXENT 24-week readout on track for 2H 2026
• ·Further clinical trial plans for zumilokibart in asthma and eosinophilic esophagitis to be announced 2H 2026
• ·Conference call and webcast held March 23, 2026 at 8:00 a.m. ET

23-03-2026

Cabaletta Bio reported Q4 and FY 2025 financial results showing increased R&D expenses of $36.2M (up 42% YoY) and $142.7M (up 47% YoY), respectively, driving a FY net loss of $167.9M (worse than $115.9M in 2024), though G&A expenses declined 22% to $6.4M in Q4. Cash position stood at $133.6M as of Dec 31, 2025 (down 19% from $164.0M prior year), extended by $30M raised post-period to fund operations into Q4 2026. Clinical progress includes rese-cel myositis BLA on track for 2027, no-preconditioning data expected 1H26, and automated manufacturing underway, with complete Phase 1/2 data from multiple RESET trials in 1H26.

• ·Registrational DM/ASyS cohort in RESET-Myositis enrolling 17 patients with 16-week primary endpoint.
• ·First clinical experience with Cellares automated manufacturing expected 1H26; longer-term data 2H26.
• ·In first 40 rese-cel patients with preconditioning: 95% no/Grade 1 CRS, 95% no ICANS.
• ·Cash runway extended to Q4 2026 with post-period $30M raise.
• ·Oral presentation on RESET-MG data at AAN Annual Meeting, April 20, 2026.

23-03-2026

Arbutus reported year-end 2025 financial results with revenue up 128% YoY to $14.1M from $6.2M due to deferred revenue recognition, R&D expenses down 53% to $25.2M from $54.0M, G&A down 28% to $15.9M from $22.1M, and net loss narrowed 52% to $33.5M ($0.17/share) from $69.9M ($0.38/share). However, cash and equivalents fell 25% to $91.5M from $122.6M amid $39.6M operating cash use and $12.9M restructuring costs, while royalty revenue declined due to lower Alnylam ONPATTRO sales. Major positives include a $2.25B Moderna LNP settlement ($950M upfront July 2026, $1.3B contingent; Arbutus entitled to 20% of noncontingent after costs) and two additional imdusiran Phase 2a functional cures (total 10 patients).

• ·Restructuring costs of $12.9M for 2025, with remaining payments expected by Q1 2026.
• ·Arbutus owns approximately 16% of Genevant's outstanding common equity.
• ·41 additional patients remained off NA therapy for at least 48 weeks in Phase 2a trials.
• ·Claim construction hearing vs. Pfizer/BioNTech in Dec 2024; ruling Sep 2025 favorable to Arbutus.

23-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 23, 2026, announcing the issuance of a press release regarding the integration of RAD devices into the Immix platform by AITX's RAD and Immix entities. No financial metrics, performance comparisons, or quantitative impacts were disclosed in the filing.

23-03-2026

Honeywell International Inc. announced the results as of March 19, 2026, and pricing for its tender offers to purchase certain existing debt securities, with settlement expected on March 24, 2026. Upon settlement, the special mandatory redemption obligation on $10B aggregate principal amount of Honeywell Aerospace senior notes (including $1.25B 3.900% due 2028, $1.25B 4.000% due 2029, and others up to 4.950% due 2036) will cease. This supports the planned Spin-Off of Honeywell Aerospace Inc.

• ·Tender offer results cutoff: 5:00 p.m. New York City time on March 19, 2026.
• ·Press releases on tender offer results (Exhibit 99.1) and pricing (Exhibit 99.2) dated March 20, 2026.
• ·Honeywell common stock and various senior notes traded on Nasdaq Stock Market LLC.

23-03-2026

Heritage Financial Corporation detected a cybersecurity incident on March 2, 2026, involving unauthorized access and exfiltration of files from an internal employee file share server that may contain personal information. While customer accounts, systems, and operations were unaffected with no disruptions to business continuity, the company has launched an investigation with external forensic and legal advisors and notified regulators, law enforcement, and its cyber insurance carrier. As of the March 20, 2026 report date, the incident has not been determined to be material or likely to impact financial condition or results of operations.

• ·Affected system taken offline to contain the incident.
• ·Incident reported under Item 8.01 Other Events in Form 8-K filed March 23, 2026.

23-03-2026

Verde Clean Fuels, Inc. appointed George Burdette, its current CFO since October 2024, as new CEO, succeeding Ernie Miller who is stepping down to pursue other opportunities but will remain as a senior advisor. The company engaged Roth Capital Partners as a financial advisor to evaluate strategic alternatives, including potential merger, sale, or other transactions involving its STG+® technology, as part of ongoing restructuring and cost reduction initiatives. While positioned as a step to maximize shareholder value through capital-lite opportunities, the process has no set timetable and no assurance of any transaction.

• ·George Burdette previously served as CFO of Arbor Renewable Gas and Itafos, and head of project finance at First Solar.
• ·No binding agreements entered for strategic alternatives; company does not intend to disclose developments unless required.
• ·Announcement dated March 20, 2026; SEC filing March 23, 2026.

23-03-2026

Core Laboratories Inc. reported total revenue of $527M in 2025, up a modest 0.5% YoY from $524M, driven by 2.9% growth in services to $399M, while product sales declined 6.3% to $127M. Operating income fell 3.6% to $56M and net income attributable to the company decreased 5.5% to $30M with diluted EPS at $0.63, down 4.5%. Free cash flow was $26M, down sharply from $44M, though long-term debt net was reduced to $110M from $126M.

• ·Current ratio declined to 2.02:1 in 2025 from 2.16:1 in 2024.
• ·Debt to EBITDA ratio improved to 1.20:1 in 2025 from 1.37:1 in 2024.
• ·Credit facility balance reduced to $3M in 2025 from $18M in 2024.
• ·Senior Notes maturities: Series A 2021 at 4.09% due Jan 12, 2026 ($45M); others unchanged.
• ·Accounts receivable allowance for credit losses increased to $6.3M in 2025 from $3.2M in 2024.
• ·Inventories decreased to $54M in 2025 from $59M in 2024.

23-03-2026

Finwise Bancorp reported net income of $16.1M for the year ended December 31, 2025, up 26% from $12.7M in 2024, fueled by non-interest income surging 160% to $58.5M and net interest income growing 23% to $72.2M, alongside total assets expanding 31% to $977M and deposits rising 38.5% to $755M. However, provisions for credit losses ballooned to $38.6M from $11.6M, non-interest expenses increased 33% to $70.3M, net interest margin declined to 9.23% from 9.99%, and total equity to assets ratio fell to 19.8% from 23.3%. Segment-wise, BaaS contributed strongly with $10.5M net income, but Traditional Banking net income was $2.9M.

• ·BaaS segment net income $10.5M, Traditional Banking $2.9M, Treasury/Other $2.7M.
• ·Loans held-for-investment net grew 20.9% to $541.6M.
• ·Credit enhancement income $23.9M (up 21,453%), but related expenses surged (servicing +112,135%, guarantee +111,846%).
• ·Average yield on loans held-for-investment declined to 12.17% from 12.27%, net of credit enhancement to 10.35% from 12.27%.

23-03-2026

Technology & Telecommunication Acquisition Corp (TETE) has filed a DEFM14A proxy statement dated March 23, 2026, for an extraordinary general meeting on or after the record date of February 25, 2026, to approve a Business Combination with Super Apps and Holdings, resulting in PubCo listing on Nasdaq as RADB, subject to approval. Post-merger ownership remains stable across minimum, mid-point, and maximum redemption scenarios, with Holdings shareholders at 85.3-85.4% (basic) or 58.4% (fully diluted), Sponsor at 10.7%/9.3%, and public shareholders at a low 1.6-1.7%/29.7%; a $5.0M PIPE is committed (with $16.0M interest), but the trust account holds only $142,275.91 as of February 23, 2026, signaling potentially high redemptions. The merger will make PubCo a controlled company with Bradbury Private Investment XVIII holding 34.5% voting power, and includes Sponsor forfeitures of 447,952 shares and contingent shares to MobilityOne.

• ·Non-Redemption Agreements dated January 19, 2025 (150,000 shares forfeited) and April 14, 2025 (297,952 shares forfeited), terminated but forfeiture obligation survives.
• ·TETE incorporated November 8, 2021; Class A shares, warrants, units listed on OTC Pink Current January 23, 2025 under TETEF, TETWF, TETUF.
• ·Nasdaq listing approval for RADB is a closing condition, waivable by Holdings and Super Apps.
• ·Shareholder meeting requests for additional documents by March 19, 2026.

23-03-2026

Lithium Argentina AG's 20-F annual report details total capital expenditures of $3.3B across Phases 1-3 of its lithium project, enabling expanded production of 153K tons LCE annually with projected revenues of $2.83B, pre-tax NPV of $7.88B at 10% discount rate, and pre-tax IRR of 37%. While initial Phase 1 capex is $1.12B supporting 51K tons LCE, the equity incentive plan burn rate increased to 3.00% in 2025 from 1.99% in 2024 amid rising awards.

• ·Average Selling Price LCE: $18,000 per ton; LHM: $17,800 per ton.
• ·Non-employee director annual award limit: US$150,000 aggregate value.
• ·Insider award caps: 10% of shares for all insiders (any time/one-year), 5% for any one insider (one-year).

23-03-2026

Sealed Air Corporation announced on March 23, 2026, that it has received all regulatory approvals required to complete its pending acquisition pursuant to the Agreement and Plan of Merger dated November 16, 2025, with Sword Purchaser, LLC (affiliated with Clayton, Dubilier & Rice, LLC) and Sword Merger Sub, Inc. The transaction is expected to close in April 2026, subject to the satisfaction of remaining customary closing conditions. A press release detailing the update is attached as Exhibit 99.1.

• ·Merger agreement dated November 16, 2025
• ·Registrant details: Delaware incorporation, Commission File Number 1-12139, IRS EIN 65-0654331, principal offices at 2415 Cascade Pointe Boulevard, Charlotte, North Carolina 28208

23-03-2026

InMed Pharmaceuticals Inc. filed a Form 8-K on March 23, 2026, disclosing under Item 7.01 positive data from human brain organoid neuroinflammation models supporting its INM-901 Alzheimer's disease program. The announcement includes Exhibit 99.1, a news release dated March 23, 2026, furnished but not filed for liability purposes. Signed by Eric A. Adams, President & CEO.

23-03-2026

BARK, Inc. filed an 8-K on March 23, 2026, disclosing a press release (Exhibit 99.1) updating on recent cost reduction initiatives and the status of potential refunds for tariffs previously paid under the International Emergency Economic Powers Act. No quantitative financial impacts, outcomes, or period-over-period comparisons were provided in the filing.

23-03-2026

This DEF 14A proxy statement, filed March 23, 2026, seeks shareholder approval to elect four Class I directors (Jennifer L. DiMotta, Jeffrey G. Ludwig, Richard T. Ramos, Jeffrey C. Smith) for terms expiring in 2029, with detailed biographies for nominees and continuing directors. Nonemployee directors receive $40,000-$85,000 annual cash retainers, committee fees ($3,000-$18,000), and $45,000 in fully vested RSUs granted June 30, 2025 (FMV $17.32/share), with special cash arrangements for James F. Deutsch paid to Patriot Financial Partners. Corporate responsibility highlights include solar power at 22 locations, 60% paperless customers, $2.0M in foundation donations since 2011, and 500 volunteer hours in 2025, with no performance declines noted.

• ·Ms. Edwards resigned from the board effective May 12, 2025.
• ·James F. Deutsch appointed to the board on February 3, 2026; his compensation paid to Patriot Financial Partners in cash instead of equity.
• ·Board structure: Class I (expiring 2029), Class II (2027), Class III (2028); Chair and CEO roles separate since 1988; all non-CEO directors independent.
• ·Company history: Over 140 years; female board member since 1903; diverse representation since before 2016 IPO.

23-03-2026

On March 19, 2026, Barnwell Industries, Inc. issued a press release highlighting its Canadian oil production assets in light of recent increases in global energy prices. The release also provides an update on the Company's ongoing evaluation of strategic alternatives for those assets. The 8-K was filed on March 23, 2026, with the press release attached as Exhibit 99.1.

23-03-2026

rYojbaba Co., Ltd. (RYOJ) filed its annual 20-F report on March 23, 2026, providing the table of contents and cautionary notes on forward-looking statements, with extensive disclosures on company risks including capital needs, PFIC status, competition in labor consulting and osteopathic clinic/beauty salon businesses, client concentration, geographic focus on Kyushu/Fukuoka, regulatory changes, and operational vulnerabilities like natural disasters and cybersecurity. No financial performance metrics, period-over-period comparisons, or quantitative data are included in the provided content. The report highlights potential dilution from fundraising and challenges in expansion, talent retention, and compliance.

23-03-2026

Opus Genetics, Inc. (IRD) has issued its definitive proxy statement for the 2026 annual stockholder meeting on April 20, 2026, virtually at www.virtualshareholdermeeting.com/IRD2026, with record date March 5, 2026. Stockholders will vote on electing nine director nominees, advisory ratification of Ernst & Young LLP as auditors for FY ending December 31, 2026, advisory approval of named executive officer compensation, and amending the Restated Certificate of Incorporation to increase authorized common shares from 125 million to 250 million. The Board recommends FOR all proposals and highlights strong corporate governance, including independent committees, declassified board, and engagement with investors representing 53% of shares as of December 31, 2025.

• ·Meeting address: 8 Davis Drive, Suite 220, Durham, NC 27713.
• ·Average director tenure under four years; all incumbent directors attended all 2025 Board meetings.
• ·Stockholders holding 20% of shares can call special meeting; no poison pill or stock hedging by directors/officers.

23-03-2026

Talphera, Inc. reported research and development expenses of $6.0M for the year ended December 31, 2025, down 10% YoY from $6.7M, and selling, general, and administrative expenses of $7.5M, down 12% YoY from $8.5M, indicating effective cost reductions. However, total other expense net swung to a $0.9M loss from $2.2M income in 2024, a 139% decline driven by losses on warrant liability and absence of prior gains. Net cash used in operating activities improved to $11.4M from $12.7M YoY, but investing activities reflected a $14.3M outflow compared to a $3.8M inflow prior year.

• ·Gain on sale of future payments was $0 in 2025 vs. $1.2M in 2024 (-100%).
• ·(Loss) gain on change in fair value of warrant liability was $1.3M loss in 2025 vs. $0.7M gain in 2024 (-283%).
• ·Non-cash interest expense on liability related to sale of future payments was $0 in 2025 vs. $0.4M expense in 2024.
• ·Net cash provided by financing activities increased to $22.7M in 2025 from $12.0M in 2024.
• ·Ongoing capital needs include FDA regulatory applications and clinical trial completion for Niyad.

23-03-2026

Yunhong Green CTI Ltd reported net sales growth of 10% YoY to $19.7M for the year ended December 31, 2025 from $18.0M in 2024, driven by foil balloons (+11% to $12.8M, 65% of sales) and film products (+33% to $1.1M), while other products grew modestly 4% to $5.8M. However, Customer B sales declined 8% to $7.9M (40% of revenues from 47%), the company recorded a $1.7M impairment on Hubei assets (vs $0 prior year), and depreciation doubled to $641k. Management remains focused on core foil balloon products and leveraging Yunhong Group advancements in compostable materials.

• ·Credit facility entered September 2021, extended in 2025, expires April 2028; in compliance since inception.
• ·55,600 shares under option outstanding and exercisable at Dec 31, 2025, weighted average exercise price $15.20 (unchanged from 2024).
• ·Two customers (A and B) represent 81% of 2025 revenues.

23-03-2026

Bionano Genomics reported Q4 2025 total revenue of $8.0 million, down 3% YoY from $8.2 million, with flowcell sales declining 6% to 7,554 units, while full-year 2025 revenue fell 7% to $28.5 million from $30.8 million due to lower instrument sales ($6.4 million vs. $8.0 million) and discontinued clinical services. However, consumables and software revenues increased 7% for the full year, gross margins improved significantly to 46% from 1%, operating expenses were cut 55% to $46.5 million, and the installed base of OGM systems grew 4% to 387. The company ended 2025 with $29.6 million in cash and initiated 2026 revenue guidance of $30-33 million.

• ·Q1 2026 revenue guidance: $6.5-6.7 million
• ·FY 2026 revenue guidance: $30-33 million
• ·Non-GAAP gross margin FY 2025: 47% (vs. 35% in 2024)
• ·9 new OGM systems installed and 6 brought back in Q4 2025
• ·32 new OGM systems installed and 16 brought back in FY 2025

23-03-2026

TGE Value Creative Solutions Corp, a SPAC formed on June 13, 2025, reported total assets of $150.8M as of December 31, 2025, primarily from $150.1M in trust account investments related to 15M Class A ordinary shares at $10.01 per share redemption value. The company recorded a net income of $146K for the period from inception through year-end, driven by $236K in other income including trust interest and fair value changes, despite a $90K operating loss. However, shareholders' deficit stood at $5.58M, largely due to $12M accretion of redeemable shares.

• ·Promissory note to related party: $150K
• ·Deferred underwriting commissions: $6M (non-current liability)
• ·Basic and diluted EPS for Class A and B shares: $0.03
• ·Class B shares initially issued to Sponsor: 5,750,000 for $25K, with 750,000 forfeited

23-03-2026

Goldenstone Acquisition Limited adopted Amendment No. 4 to its Amended and Restated Certificate of Incorporation, extending the Termination Date for consummating a Business Combination to December 21, 2026, from a prior date, and changing the corporate name to Chi Special Acquisition Corp. The amendment also deletes the last sentence of paragraph D in Article Sixth and restates provisions for redemption and liquidation of IPO Shares if no business combination occurs by the new deadline. It was duly approved by the Board of Directors and stockholders, and executed by CEO Eddie Ni.

• ·Original Certificate filed September 9, 2020.
• ·Prior amendments: March 16, 2022 (IPO-related), September 21, 2023, June 18, 2024, June 18, 2025.
• ·Redemption price: pro rata share of Trust Account plus pro rata interest earned (net of taxes), divided by outstanding IPO Shares.

23-03-2026

Catheter Precision, Inc. (VTAK) completed Initial and Subsequent Series C Private Placements raising aggregate gross proceeds of $3.47M through issuance of 392,608 common shares and 3,470 Series C-1 Preferred shares convertible into up to 2,426,573 common shares at $1.43 initial conversion price. The proxy seeks stockholder approval for conversion of these and potential additional Series C-2, C-3, and up to $77.8M in C-4 Preferred shares (total potential up to $88.2M), as required under NYSE American rules for issuances exceeding 19.99% of outstanding common stock or voting power. No stockholder approval has been obtained yet, delaying full conversion and additional closings.

• ·Stockholder meeting required within 60 days of February 9, 2026 Initial Closing Date; if not approved, reconvene every 90 days until obtained or preferred shares redeemed.
• ·Series C Preferred conversion prices adjustable to 80% of applicable price (5-day VWAP or closing price) post-Effective Date or Stockholder Approval Date, subject to $0.35 floor (waivable by Company).
• ·Placement agent Dawson James entitled to 7.7% cash fee only on proceeds above $3.85M.
• ·Preferred stockholders have protective veto rights on adverse changes to terms, charter amendments affecting rights, or increasing authorized preferred shares.

23-03-2026

Appendix B of the BANK5 2023-5YR2 10-K filing details compliance assertions by multiple servicers (CWCAM, PBLS1, Midland, CoreLogic) with Regulation AB servicing criteria for asset-backed securities, primarily mortgage loan pools. Most applicable criteria are marked as performed directly by the company or responsible vendors, with several investor reporting and pool administration items designated as not applicable or not performed due to transaction structure. No material deficiencies or exceptions are reported across general servicing, cash collection, and asset administration categories.

• ·Filing date: March 23, 2026
• ·Standard timeframes referenced include deposits/postings within 2 business days, reconciliations within 30 calendar days, and resolution of reconciling items within 90 calendar days
• ·Multiple criteria (e.g., 1122(d)(1)(iii), 1122(d)(3)(ii)-(iv), various 1122(d)(4) items) marked as Not Applicable or Inapplicable across servicers

23-03-2026

General Motors Company and General Motors Financial Company, Inc. entered into the Eighth Amended and Restated 364-Day Revolving Credit Agreement dated March 23, 2026, amending and restating the prior Seventh Amended and Restated agreement from March 25, 2025. The facility involves multiple lenders, with JPMorgan Chase Bank, N.A. as Administrative Agent and Citibank, N.A. as Syndication Agent, along with various joint lead arrangers and bookrunners. No specific commitment amounts, pricing grids, or changes in terms are detailed in the filing excerpt.

• ·Filing Type: 8-K, Items: 1.01, 2.03, 9.01
• ·Previous credit agreement effective date: March 25, 2025
• ·Schedules include Commitments (1.1A), Applicable Pricing Grid (1.1C), but details redacted or not provided

23-03-2026

J. Derek Lewis & Associates Inc. filed its 13F-HR on March 23, 2026, disclosing equity holdings as of December 31, 2025, totaling $426.9 million across 209 positions held solely. Top holdings include Capital Group Core Balanced ($40.5M, 1,146,334 shares), Capital Group Dividend Value ($31.4M, 719,370 shares), and Apple Inc. ($18.9M, 69,651 shares), with significant allocations to other Capital Group ETFs/mutual funds, Microsoft ($7.9M), and NVIDIA ($5.2M). No voting or disposition power sharing reported for any positions.

• ·Holdings period end date: December 31, 2025
• ·All positions reported with sole voting and disposition power; no shared power indicated
• ·Heavy concentration in Capital Group ETFs and mutual funds comprising a significant portion of total AUM

23-03-2026

General Motors Company and General Motors Financial Company, Inc. entered into the Eighth Amended and Restated 364-Day Revolving Credit Agreement dated March 23, 2026, amending and restating the prior Seventh Amended and Restated agreement from March 25, 2025. The facility involves multiple lenders led by JPMorgan Chase Bank, N.A. as Administrative Agent and Citibank, N.A. as Syndication Agent, with terms including commitments detailed in Schedule 1.1A (not specified in excerpt) and standard covenants such as minimum liquidity and indebtedness restrictions. No quantitative changes or performance metrics are disclosed in the filing.

• ·Agreement replaces Seventh Amended and Restated 364-Day Revolving Credit Agreement dated March 25, 2025.
• ·References related facilities: Sixth Amended and Restated Three Year Revolving Credit Agreement and Fifth Amended and Restated Five Year Revolving Credit Agreement, both dated March 25, 2025.
• ·Covenants include Minimum Liquidity (Section 7.1), Indebtedness limits (Section 7.2), and Asset Sale Restrictions (Section 7.3).

23-03-2026

Slide Insurance Holdings, Inc. announced on March 23, 2026, that its Board of Directors authorized a common stock repurchase program of up to $125 million. The program has no expiration date and permits repurchases via open market transactions, privately negotiated deals, Rule 10b5-1 plans, or other methods, subject to stock price, trading volume, legal requirements, and market conditions. The company is not obligated to repurchase any shares.

23-03-2026

Hewlett Packard Enterprise Company completed an underwritten public offering of $2.0B in senior notes on March 23, 2026, comprising $300M Floating Rate Notes due 2028, $500M 4.500% Notes due 2028, $600M 4.600% Notes due 2029, and $600M 5.250% Notes due 2033. The notes were issued pursuant to a base indenture dated October 9, 2015, supplemented by four new supplemental indentures with The Bank of New York Mellon Trust Company, N.A. as trustee, and registered under Form S-3 (No. 333-276221). No financial performance metrics or period comparisons were disclosed.

• ·Registration statement on Form S-3 (No. 333-276221), effective December 22, 2023.
• ·Base Indenture dated October 9, 2015; Supplemental Indentures: Thirty-Second (Floating Rate Notes), Thirty-Third (2028 Notes), Thirty-Fourth (2029 Notes), Thirty-Fifth (2033 Notes), all dated March 23, 2026.

23-03-2026

The Cato Corporation reported a narrowed Q4 FY2025 net loss of $10.7 million ($0.55 per diluted share) versus $14.1 million ($0.74 per diluted share) in Q4 FY2024, though sales declined 3.4% to $150.0 million with same-store sales flat. Full-year FY2025 net loss improved to $5.9 million ($0.31 per diluted share) from $18.1 million ($0.97 per diluted share), with sales up a modest 0.7% to $646.8 million and same-store sales increasing 4%, supported by gross margin expansion to 33.3% from 32.0% and SG&A reduction. However, the company closed 48 stores, reducing its footprint to 1,069 locations from 1,117, amid plans to open up to 10 and close up to 40 more in FY2026.

• ·Q4 gross margin: 29.2% vs 28.0% prior year.
• ·FY2025 SG&A expenses: 35.0% of sales vs 36.0% prior year.
• ·Cash and equivalents: $16.8M as of Jan 31, 2026 vs $20.3M prior year-end.
• ·Plans for FY2026: open up to 10 new stores, close up to 40 underperforming stores.

23-03-2026

MediaAlpha, Inc. filed a DEFA14A Definitive Additional Proxy Materials on March 23, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is categorized as Definitive Additional Materials, with no substantive financial or operational updates provided in the header content.

23-03-2026

Comtech Telecommunications Corp. filed a Form S-3 shelf registration statement with the SEC on March 23, 2026, enabling the potential offering of up to $125 million in common stock, preferred stock, debt securities, warrants, purchase contracts, or units from time to time based on market conditions. The company's common stock (CMTL) had a last reported sale price of $3.66 per share on March 17, 2026, and trades on the Nasdaq Global Select Market. As a smaller reporting company, Comtech qualifies due to non-affiliate market value under $250M or annual revenue under $100M, allowing reduced disclosure obligations.

• ·Principal executive offices: 305 N 54th Street, Chandler, Arizona 85226; Phone: (480) 333-2200
• ·Incorporated in Delaware; I.R.S. Employer Identification Number: 11-2139466; Founded: 1967
• ·Reportable segments: Allerium (formerly Terrestrial and Wireless Networks) and Satellite and Space Communications

23-03-2026

Surrozen reported a FY 2025 net loss of $242.0M, up significantly from $63.6M in 2024, driven by large non-cash losses including $112.0M from changes in fair value of tranche liability and $71.1M from 2025 PIPE execution, while Q4 net loss was $183.2M versus $28.0M in Q4 2024. Revenue fell to $3.5M from $10.7M YoY due to no collaboration revenue, though cash grew to $89.2M from $34.6M and a $5M milestone was triggered by Boehringer Ingelheim. The company advanced its ophthalmology pipeline with IND submission for SZN-8141 planned for H2 2026 and strengthened leadership.

• ·Collaboration with TCGFB, Inc. for TGF-β antibodies research terminated in November 2025.
• ·IND-enabling GLP toxicology study for SZN-413 achieved milestone in March 2026.
• ·ARVO Annual Meeting poster presentation scheduled for May 4, 2026.

23-03-2026

Sonoco Products Company entered into a $300M Term Credit Agreement on March 23, 2026, with Wells Fargo Bank, National Association as Administrative Agent and Wells Fargo Securities, LLC as lead arranger, providing aggregate commitments of $300M for loans to the borrower. Interest rates for Term SOFR/Daily Simple SOFR Loans range from 0.850% (Pricing Level I) to 1.100% (Pricing Level III) based on S&P/Moody's debt ratings, with a ticking fee of 0.125% per annum initially, increasing to 0.250% after 91 days. No performance declines or flat metrics are mentioned in the agreement.

• ·Audited Financial Statements reference consolidated balance sheet as of December 31, 2025.
• ·Base Rate floor of 1.00%.
• ·Debt Ratings determine pricing levels: Level I (≥ BBB/Baa2), II (BBB-/Baa3), III (≤ BB+/Ba1).

23-03-2026

M2i Global, Inc. settled a lawsuit filed on June 18, 2025, by James Bernet, Kelsey James, LLC, and BCA Cares, LLC alleging breach of contract and securities fraud from 2022-2023 agreements, following a default judgment entered on November 12, 2025, awarding plaintiffs $18M in damages or 100M shares. Under the March 19, 2026, Settlement Agreement, the company will issue 12.5M common shares to James Bernet (with leak-out provisions), enabling mutual releases, dismissal of the action, and setting aside of the judgment, avoiding cash payment but resulting in shareholder dilution. The company's February 12, 2026, motion to set aside the judgment remains pending until shares are transferred.

• ·Lawsuit filed in District Court of Washoe County, Nevada.
• ·Motion to set aside default judgment filed February 12, 2026, pending before Second Judicial District Court of the State of Nevada.
• ·Settlement shares transfer to initiate within 5 business days of March 19, 2026, agreement; stipulation to dismiss within 5 days of Bernet's receipt.
• ·No admission of wrongdoing in settlement.

23-03-2026

Waters Corporation's subsidiary, Augusta SpinCo Corporation, completed a $3.5B public offering of senior notes consisting of $650M 4.321% due 2027, $600M 4.398% due 2029, $750M 4.656% due 2031, $750M 4.945% due 2033, and $750M 5.245% due 2036, fully guaranteed by Waters and certain subsidiaries. The notes were issued under an indenture with covenants limiting liens, sale-leasebacks, and mergers, and include customary redemption and change of control repurchase rights. Net proceeds, along with cash on hand, will repay $3.5B of a delayed draw term loan from February 2026.

• ·Notes redeemable at Issuer's option (except 2027 Notes) at prices per Indenture terms.
• ·Change of control triggering events allow holders to require repurchase at 101% of principal plus accrued interest.
• ·Indenture covenants limit liens, sale-leaseback transactions, and require conditions for mergers.
• ·Underwriting agreement dated March 17, 2026, with listed representatives.

23-03-2026

Richmond Mutual Bancorporation, Inc. (RMBI) and The Farmers Bancorp, Frankfort, Indiana entered into a merger agreement on November 11, 2025, pursuant to which Farmers Bancorp will merge into RMBI, creating a combined bank holding company with approximately $2.6B in total assets and 25 branches across Indiana and Ohio. Farmers Bancorp shareholders will receive 3.40 shares of RMBI common stock per share (exchange ratio), valued at approximately $44.71 per share or $82.4M aggregate based on RMBI's closing price on the announcement date, with former Farmers shareholders owning ~38% of the combined company post-merger. The transaction is subject to shareholder approval at meetings in 2026 and includes standard risks such as potential changes in RMBI stock value.

• ·Merger agreement dated November 11, 2025; S-4 filing date March 23, 2026.
• ·RMBI trades on NASDAQ under 'RMBI'; Farmers Bancorp on OTC Pink under 'FABP'.
• ·Merger expected to qualify as tax-free reorganization under IRC Section 368(a), except for cash in lieu of fractional shares.
• ·Shareholder meetings: RMBI annual meeting and Farmers Bancorp special meeting scheduled for [·], 2026.
• ·I.R.S. Employer Identification No. for RMBI: 36-4926041.

23-03-2026

Phillips Edison & Company, Inc. (PECO) filed a DEFA14A Definitive Additional Materials proxy statement on March 23, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing contains no substantive details, proposals, financial data, or period-over-period comparisons in the provided content.

• ·Filing Type: DEFA14A (Definitive Additional Materials)
• ·No fee required for filing

23-03-2026

SolarEdge Technologies reported revenues of $1.18B for the year ended December 31, 2025, up 31.4% YoY from $0.90B, driven by higher recognition of inverters (349.6K units, +42%), power optimizers (10.6M units, +59%), and battery MWh (897.4, +61%). Gross profit swung to $196M from a $877M loss, aided by a $758M decrease in inventory costs from write-downs and 40% lower operating expenses via workforce reductions; however, the company still posted a net loss of $405M (improved 77.6% from $1.81B loss), with financial expenses surging 394%.

• ·Inverters recognized as revenue increased to 349.6K units in 2025 from 245.7K in 2024 (+42%).
• ·Power optimizers recognized as revenue: 10,571.4K units in 2025 vs 6,645.8K in 2024 (+59%).
• ·Battery MWh recognized as revenue: 897.4 in 2025 vs 556.2 in 2024 (+61%).
• ·Research and development expenses down 20.2% to $221.3M.
• ·Financial expense, net worsened to $72M (+394%).

23-03-2026

Ballston Spa Bancorp, Inc. held a Special Meeting of Shareholders on March 23, 2026, approving the merger with NBC Bancorp, Inc. (Agreement dated September 23, 2025) with 593,057 votes in favor, 745 against, and 5,324 abstentions out of 742,663 outstanding shares, meeting the two-thirds requirement. NBC Bancorp's shareholders also approved the merger on the same date, with closing anticipated subject to customary conditions. A joint press release was issued announcing the approvals.

• ·Common Stock trades as BSPA on OTCQX, par value $12.50 per share
• ·Registrant is an emerging growth company
• ·No adjournment proposal vote needed due to merger approval

23-03-2026

Barings Private Credit Corporation sold 4,923,488 unregistered shares of common stock for approximately $99.3M as of March 2, 2026, pursuant to its ongoing private offering. The Board declared a regular monthly distribution of $0.175 per share for April 2026, payable on April 29 to stockholders of record on April 27. As of February 28, 2026, NAV per share was $20.17, with $3.1B raised from 150.6M shares issued to date in the continuous private offering targeting up to $4.5B.

• ·Private offering exempt under Section 4(a)(2), Regulation D, and/or Regulation S of Securities Act
• ·Per share price for sold shares determined per Section 23 of Investment Company Act of 1940
• ·Company is emerging growth company

23-03-2026

Guardian Pharmacy Services, Inc. entered into Stock Purchase Agreements on March 18, 2026, to repurchase up to 1,833,344 shares of Class A common stock using proceeds from public offerings, and consummated an underwritten public offering on March 20, 2026, of 6,900,000 shares at $31.00 per share (5,880,000 from selling stockholders and 1,020,000 newly issued by the company, with proceeds used to repurchase and cancel an equivalent number of shares, resulting in no change to outstanding shares). The offering was non-dilutive but led to the loss of controlled company status under NYSE rules, requiring the establishment of an independent Nominating and Governance Committee. Selling stockholders, including Bindley Capital Partners I, LLC and others, are subject to a lock-up until the later of June 30, 2026, or 180 days after the latest underwriting agreement.

• ·Stock Purchase Agreements executed March 18, 2026; Offering consummated March 20, 2026; Filing dated March 23, 2026.
• ·Company qualified as controlled company prior to Offering due to majority voting power held by selling stockholders; now subject to full NYSE governance requirements with transition periods.